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RESEARCH Open Access
A randomised trial of non-invasive cardiac
output monitoring to guide haemodynamic
optimisation in high risk patients undergoing
urgent surgical repair of proximal femoral
fractures (ClearNOF trial NCT02382185)
S. J. Davies1*, D. R. Yates1, R. J. T. Wilson1, Z. Murphy1, A. Gibson2, V. Allgar3 and T. Collyer4
Abstract
Background: Hip fracture is a procedure with high mortality and complication rates, and there exists a group
especially at risk of these outcomes identified by their Nottingham Hip Fracture Score (NHFS). Meta-analysis
suggests a possible benefit to this patient group from intravascular volume optimisation. We investigated whether
intraoperative fluid and blood pressure optimisation improved complications in this group.
Methods: Patients with a NHFS ≥ 5 were enrolled into this multicentre observer-blinded randomised control trial.
Patients were allocated to either standard care or a combination of fluid optimisation and blood pressure control using a
non-invasive system. The primary outcome was the number of patients with one or more complications in each group.
Secondary outcomes included hospital length of stay (LOS), incidence of hypotension and fluid and vasopressor usage.
Results: Forty-six percent of patients in the intervention group suffered one or more complications compared to the
51% in the control group (OR 0.82 (95% CI 0.49–1.36)). Per-protocol analysis improved the OR to 0.73 (95% CI 0.43–1.24).
Median LOS was the same between both groups; however, the mean LOS on a per-protocol analysis was longer in the
control group compared to the intervention group (23.2 (18.0) days vs. 18.5 (16.5), p = 0.047).
Conclusions: Haemodynamic optimisation including blood pressure management in high-risk patients undergoing
repair of a hip fracture did not result in a statistically significant reduction in complications; however, a potential
reduction in length of stay was seen.
Trial registration: A randomised trial of non-invasive cardiac output monitoring to guide haemodynamic optimisation in
high risk patients undergoing urgent surgical repair of proximal femoral fractures (ClearNOF trial NCT02382185).
Keywords: Hemodynamic, Cardiac Output, Femoral neck fracture
Background
It is estimated that the number of patients that will
sustain a hip fracture will reach 100,000 per annum by
2033 with a cost to the UK health services alone of some
£ 2.7 billion (White & Griffiths, 2011). Outcomes for
this group remain poor with a mortality of 6% at 1
month, increasing to 20–33% (Brauer et al., 2009; Hip
Fracture Anaesthesia Sprint Audit Project, n.d.) at 1 year
(The National Hip Fracture Database, 2016). Complica-
tion rates for this group also remain significant with
between 20 and 60% of patients having significant post-
operative complications (Roche et al., 2005; Bartha et al.,
2013). These complications are not only associated with
increased length of stay and healthcare costs, but also
reduced long-term survival (Lawrence et al., 2002; Khuri
et al., 2005).
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Attempts to improve outcomes through fluid opti-
misation protocols have been mixed (Bartha et al., 2013;
Sinclair et al., 1997; Venn et al., 2002) with the most re-
cent work (Moppett et al., 2015) suggesting that fluid
optimisation using an arterial waveform-based system
did not reduce complications or mortality, although a
recent meta-analysis shows a trend towards both. The
authors suggested that the role of tighter arterial pres-
sure control should be addressed as part of any future
intervention. Given that the incidence of hypotension in
the Anaesthesia Sprint Audit of Practice (ASAP) (White
et al., 2016) was significant with 56% of patients under-
going neck of femur (NOF) repair having a systolic
blood pressure of less than 90mmHg, and one third
having a mean arterial pressure (MAP) of less than 55
mmHg, and the association of hypotension with adverse
events (Salmasi et al., 2017; Sun et al., 2015), this may be
a valid treatment strategy in this group.
Within this group of elderly patients, a high-risk group
exists. The Nottingham Hip Fracture Score (NHFS) is a
validated scoring system that predicts patients at in-
creased risk of both 30-day and 1-year mortality (Wiles
et al., 2011; Maxwell et al., 2008). This high-risk group,
with an increased mortality rate, may also have an in-
creased complication rate, and hence any effective inter-
vention may have a greater impact on these outcomes.
The aim of the study was to investigate the role of
haemodynamic optimisation (stroke volume optimisa-
tion and blood pressure control) in high-risk patients
defined by a NHFS ≥ 5 undergoing urgent surgical repair
of proximal femoral fractures and the effects of this on
complications. Secondary outcomes included the length
of stay, the incidence of hypotension and the use of
vasopressors and fluids.
Methods
We performed a multicentre randomised controlled
observer-blinded trial.
This study was approved by the National Research
Ethics Service (NRES) committee Yorkshire and the
Humber Leeds West (14/YH/1170). Written informed
consent was obtained by those individuals that held
capacity; otherwise, if a patient met the inclusion criteria
but lacked the capacity to consent, we followed the
process outlined in the Mental Capacity Act and approved
by the NRES committee. The trial was registered prior to
patient enrolment at clinicaltrials.gov (NCT02382185).
Study population
Patients due to undergo urgent or emergency repair of a
proximal femoral fracture with NHFS ≥ 5 were enrolled.
Patients were excluded if they were aged < 50 years, had
an American Society of Anesthesiologists (ASA) physical
status classification 5 or had multiple injuries requiring
operative management.
Randomisation, allocation and blinding
Participants were randomised on a 1:1 ratio of ‘conven-
tional fluid therapy’ (control group) or ‘haemodynamic
optimisation’ (intervention group). The randomisation
was stratified on the basis of the type of anaesthesia
(spinal or general anaesthesia) and hospital. Block ran-
domisation was used to ensure a similar number of par-
ticipants between the intervention and control groups.
The randomisation sequence was prepared using
randomisation software, and individual allocations were
concealed in sequentially numbered, sealed, opaque en-
velopes. The unopened envelopes were held securely.
The lowest available randomisation numbered envelope
was opened by the research nurse once the anaesthetic
had been performed.
Treatment of participants
Intervention group
Prior to induction of anaesthesia, an appropriately sized
ClearSight™ (Edwards Lifesciences, Irvine, USA) non-
invasive haemodynamic monitor probe was placed on a
suitable finger and baseline haemodynamic measure-
ments were taken (blood pressure, heart rate, stroke
volume, cardiac output). After induction of anaesthesia,
the participant’s stroke volume was optimised using 250
ml boluses of Hartmann’s solution. This was defined as
repeated boluses of crystalloid until a stroke volume rise
of > 10% was no longer seen. The stroke volume (SV)
measurement prior to the final fluid bolus was set as the
target SV. Once the stroke volume was optimised, mean
arterial blood pressure was maintained to within 30% of
baseline values using a peripheral phenylephrine infusion
or metaraminol infusion. Phenylephrine infusion was at
a concentration of 100 μg/ml, whilst metaraminol was at
a concentration of 500 μg/ml. Both were started at a rate
of 10 ml/h and titrated to response by alteration of the
infusion rate in increments of 2 ml/h. After titration of
the vasopressor infusion to achieve the desired mean ar-
terial pressure, if the stroke volume increased by greater
than 10% from the pre-infusion value, then this was
taken as the new baseline value against which further
decreases in stroke volume were measured. If the target
stroke volume decreased by 10%, a fluid challenge was
given, as described previously. If during stroke volume
optimisation, prior to SV maximisation, the treating clin-
ician deemed the mean arterial pressure unacceptably
low for that patient, they were permitted to administer a
bolus of vasopressor at their discretion. Due to the need
to not influence the current clinical practice excessively,
clinicians were allowed to administer ephedrine if they
felt that inotropic support was required. Data on stroke
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volume, heart rate, blood pressure, cardiac output and
oxygen saturation was recorded at baseline and then
every 20 s.
Control group
Prior to the induction of anaesthesia, a ClearSight™ non-
invasive haemodynamic monitor probe was sited and
baseline haemodynamic measurements were taken. All
fluid management and administration of inotrope or vaso-
pressor therapy were at the discretion of the anaesthetist
as per the current practice at the host institution. Only
Hartmann’s solution was used as per institutional policies.
Data on stroke volume, heart rate, blood pressure, cardiac
output and oxygen saturation were recorded at baseline
and then every 20 s. The anaesthetist was unable to see
the monitor and all alarms were silenced.
The surgeon remained blinded throughout the proced-
ure. Other members of the team attending to partici-
pants in the control group were blinded to the readings
from the monitor; however, in order to administer the
treatment, this was not possible in the intervention
group; hence, the anaesthetist was aware of the treat-
ment allocation.
Post-operatively, a research nurse or investigator who
was not present in the theatre, and therefore was blinded
to group allocation, performed the follow-up visits to as-
sess outcome measures. The post-operative case report
form (CRF) was separate from the intraoperative CRF and
the two were reconciled at the termination of the study.
Anaesthetic technique and post-operative care
Anaesthetic technique was at the discretion of the anaes-
thetist as per the current practice at the host institution
in both the treatment and control groups.
Patients were cared for following surgery in the post-
anaesthetic care unit (PACU), and post-operative main-
tenance fluid therapy was administered at a rate of 1 ml/
kg/h until oral intake was adequate. The type of crystal-
loid maintenance fluid was at the discretion of the an-
aesthetist. Fluid boluses were given if clinically indicated.
Vasopressor infusions were reduced to maintain an ac-
ceptable mean arterial pressure as determined by the an-
aesthetist until discontinued. Discharge from the PACU
was determined by local protocols.
Outcome measures
The primary outcome was the number of patients who de-
veloped one or more in-hospital post-operative complica-
tions as defined by Copeland and modified for this patient
group by Bartha (Bartha et al., 2013) (Appendix 1).
Secondary outcomes included the incidence of morbid-
ity at days 3, 5 and 10 as measured by the Post-Operative
Morbidity Survey (POMS) (Bennett-Guerrero et al., 1999),
length of stay in hospital after surgery, intraoperative
haemodynamic variables (stroke volume, heart rate, blood
pressure, cardiac output), volume of intraoperative fluid
administered, incidence of intraoperative hypotension and
the use of intraoperative vasopressor support.
Statistical analysis
A retrospective analysis of clinical notes identified that
75% of patients undergoing neck of femur repair with a
NHFS ≥ 5 had one or more complications as defined in
Appendix 1. A meta-analysis by Grocott et al. (Grocott
et al., 2013) that reviewed studies designed to increase
global blood flow as defined by explicit goals measured
either invasively or non-invasively, for example, stroke
volume, suggested a RR reduction of 0.68 for complica-
tions in patients undergoing major surgery, whilst an
economic and feasibility analysis by Bartha et al. (Bartha
et al., 2012) suggested the intervention would be cost-
effective with a modest effective size (relative risk of
0.84). A clinically significant reduction in the incidence
of complications from 60 to 42% during hospital stay
would require two groups of patients with 120 patients
per group to have an 80% power of detecting a differ-
ence with a significance of p < 0.05.
Baseline characteristics are compared descriptively in
line with CONSORT. Descriptive statistics are presented
as mean (SD), minimum-maximum, or median (inter-
quartile range (IQR)) and valid n if data is missing.
Categorical data is presented as n (%) and the valid n if
data is missing. Both intention-to-treat (ITT) and pre-
specified per-protocol (PP) analyses were performed for
the primary outcome and for the length of stay.
For the primary outcome, a chi-square test was used
to compare the proportion in each group developing
one or more in-hospital post-operative complications,
and logistic regression was used to calculate the odds
ratio.
For the secondary outcomes, chi-square tests were
used to compare proportions between groups. t tests
were used to compare continuous variables or Mann–
Whitney tests if data was non-normal or ordinal data.
The end of surgery haemodynamic data (stroke volume
and cardiac index) was compared between groups using
ANCOVA, adjusting for start of surgery values.
For blood pressure measurements for each patient, we
calculated the total operation time and for each thresh-
old (MAP 70, 65, 60, 55 and 50), and we calculated the
number of minutes below the threshold. The area under
the curve (AUC) is therefore the total time under
threshold/total operation time. We also calculated the
value of MAP as a percentage of baseline (%MAP) and
for each threshold calculated the number of minutes
below the threshold for %MAP below 10%, 20%, 30%,
40%, 50% and 60% of baseline. The AUC is therefore the
total time under threshold/total operation time.
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A p value of < 0.05 was considered to indicate statis-
tical significance. No adjustments have been made for
multiple significance testing. SPSS (V24) was used for
statistical analysis.
We updated the Cochrane systematic review using iden-
tical search criteria in Cochrane, Medline, EMBASE and
trial registries (clinicaltrials.gov and WHO). Data were
analysed using the Mantel–Haenszel random effects risk
ratios in RevMan V5.3.5.
Results
Two hundred forty-one patients were recruited and ran-
domised from November 2015 to September 2017. Con-
sort flow chart for the study is shown in Fig. 1. Patient
demographics, surgical and anaesthetic details are shown
in Table 1.
Primary outcome
Complications are shown in Table 2. On the intention-
to-treat analysis (ITT), the 55/120 (46%) subjects in the
intervention group had a complication compared to the
61/120 (51%) in the control group with an odds ratio of
0.82 (95% CI 0.49–1.36, p = 0.439).
Overall, 21 patients in the intervention group did not
receive the intervention; in 18 patients, equipment fail-
ure did not allow for the protocol to be delivered,
whilst in 2 patients, a clinical decision was made to de-
viate from the protocol, and in 1 patient, the protocol
was not correctly delivered. On a per-protocol analysis
(PP), the proportion with at least one complication in
the control group was 61/120 (51%) and 43/100 (43%)
in the intervention group (OR 0.73 (95% CI 0.43–1.24,
p = 0.247)).
Secondary outcomes
Length of stay
On ITT analysis, in the control group, the mean LOS
was 23.2 (18.0) days (median 16 (11–32)), and in the
intervention group, the mean LOS was 18.9 (16.2) days
(median 16 (11–23)). There was no statistically signifi-
cant difference between groups (p = 0.053).
Fig. 1 Consort flow diagram
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On PP analysis, in the control group, the mean LOS
was 23.2 (18.0) days (median 16 (11–32)), and in the
intervention group, the mean LOS was 18.5 (16.5) days
(median 16 (11–23)). There was a statistically significant
difference between groups (p = 0.047).
Post-operative morbidity score
There was no difference in POMS score between the
groups on any measured day (Appendix 2).
Mortality
At 30 days, in the control group, 10/120 (8%) had
died compared to 11/120 (9%) in the intervention
group (p = 0.819). At 90 days, in the control group,
27/120 (23%) had died compared to the 25/120 (21%)
in the intervention group (p = 0.754)
Fluid volumes and vasopressor doses
Fluid volumes and vasopressor dose are shown in
Table 3. The mean total fluid given was 1012.7 ml
(354.0) in the control group and 875.0 ml (456.1) in the
intervention group (p = 0.010). More patients in the
control group (47/120) received ephedrine compared to
the intervention group (17/103, p = 0.000012) and had
no statistically significant difference in the total dose.
Less patients in the control group received a vasopres-
sor (64/120) compared to the intervention group (115/
120, p < 0.00001); however, the total dose given was not
statistically significant.
Haemodynamic data
At the start of surgery, the mean stroke volume was
46 (18) ml in the control group and 42 (13) ml in
the intervention group (p = 0.009). In both groups,
the stroke volume had increased at the end of surgery
to 48 (17) ml in the control group and 46 (13) ml in
the intervention group. There was a significant differ-
ence between groups in stroke volume at the end of
Table 1 Patient demographics, surgical and anaesthetic details
Control Intervention
n = 120 n = 121
Age (years) 85.7 (7.5),
range 57–103
87.3 (6.1),
range 67–98
Gender
Female 65 (54%) 75 (62%)
Male 55 (46%) 46 (38%)
BMI (kg/m2) 23.7 (4.5) 24.0 (4.4)
BSA (m2) 1.7 (0.2) 1.7 (0.2)
Co-morbidities
Hypertension 67 (56%) 63 (53%)
Angina 14 (12%) 12 (10%)
Atrial fibrillation 24 (20%) 34 (28%)
Myocardial infarction 10 (8%) 14 (12%)
CABG 7 (6%) 2 (2%)
Heart failure 7 (6%) 2 (1.7%)
Chronic renal failure 14 (12%) 18 (15%)
Previous stroke/TIA 28 (23%) 16 (13%)
Diabetes 21 (18%) 14 (12%)
COPD 8 (7%) 13 (11%)
Baseline BP
Systolic (mmHg) 145.0 (27.8),
46–222, n = 119
142.5 (25.3),
72–231, n = 120
Diastolic (mmHg) 75.1 (14.0),
46–110, n = 119
74.1 (14.8),
32–108, n = 120
Mean (mmHg) 98.7 (17.6), 61–159 98.9 (17.9), 48–148
ASA grade
1 0 (0%) 1 (1%)
2 12 (10%) 23 (19%)
3 83 (69%) 75 (62%)
4 25 (21%) 22 (18%)
Anaesthetic
General 70 (58%) 64 (53%)
Spinal 50 (42%) 56 (47%)
Sedation (% of spinal patients) 45 (90%) 44 (77%)
Block 62 (52%) 64 (53%)
Type of block
Fascia iliaca 34 (28%) 38 (32%)
Femoral 28 (23%) 24 (20%)
Unknown 0 (0%) 1 (1%)
n/a 58 (48%) 57 (47%)
Grade of surgeon
Consultant 43 (36%) 42 (35%)
Fellow 0 (0%) 1 (1%)
SPR 55 (46%) 62 (51%)
Staff grade 22 (18%) 14 (12%)
Table 1 Patient demographics, surgical and anaesthetic details
(Continued)
Control Intervention
Not known 0 (0%) 1 (1%)
Surgery duration (mins) 69.2 (27.8), 13–181 65.0 (22.4), 6–148
Cemented implant (yes) 58 (48%) 58 (48%)
Implant
Cannulated screws 3 (3%) 3 (3%)
DHS 37 (31%) 45 (37%)
Gamma nail 13 (11%) 9 (7%)
Hemi-arthroplasty 64 (53%) 59 (49%)
THR 3 (3%) 5 (4%)
Note some percentage in each group may not add up to 100% due to rounding.
All numbers are mean (SD) and range unless otherwise expressed as a percentage
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the surgery, adjusting for start of surgery stroke
volume (p = 0.028).
At the start of surgery, the mean cardiac index was
2.0 l.min−1 m2 (0.7) in the control group and 1.8
l.min−1 m2 (0.70) ml in the intervention group (p =
0.058). In both groups, the cardiac index increased at
the end of surgery to 2.1 l.min−1 m2 (0.7) in the control
group and 1.9 l.min−1 m2 (0.6) in the intervention group.
There was no significant difference between groups at
the end of surgery, adjusting for start of surgery cardiac
index (p = 0.320).
The AUC data for the blood pressure data is shown
in Table 4. The intervention group spent less time
with an absolute MAP below 70, 65 and 60 mmHg.
As a percentage of the baseline MAP, the intervention
group spent less time below the thresholds of 60%,
50% and 40% of baseline.
There was no association between duration or magni-
tude of hypotension and complication rates or length of
stay.
Systematic review
We used the same search strategy published in the
Cochrane review (Brammar et al., 2013) and the paper
by Moppett (Moppett et al., 2015) to update the meta-
analysis using identical search criteria in Cochrane,
Medline, EMBASE and trial registries (clinicaltrials.gov
and WHO). Searches were carried out on 20 November
2018 and repeated on the 6 June 2019. Reports of recent
trials and reviews of goal-directed therapy were also
hand searched. The methods were based on the PICO
format. The eligible population was patients with hip
fracture, and the intervention was intraoperative fluid
therapy guided by cardiac output monitoring compared
with usual care. Additional trials were assessed for the
risk of bias using the Cochrane domains. We used a
shortened number of outcomes: all-cause mortality
within 30 days and the number of survivors with compli-
cations. The characteristics and risk of bias were not
different to that reported previously (Moppett et al.,
2015). We did not find any other ongoing clinical trials
or additional trials that had been performed except the
one being reported since the updated meta-analysis by
Moppett.
Data were analysed using the Mantel–Haenszel ran-
dom effects risk ratios in RevMan V5.3.
For identical reasons as Moppett, and for comparison,
we did not include the trial by Schultz and colleagues
(Schultz et al., 1985) and used only the Doppler and
control groups, not the CVP-guided group, from Venn
and colleagues.
The updated meta-analysis showed no significant effect
of the intervention on mortality (Fig. 2) but a significant
difference in morbidity: four studies, 539 patients and risk
ratio 0.82 (95% CI 0.69–0.99) (Fig. 3).
Discussion
Haemodynamic optimisation of high-risk patients
undergoing proximal neck of femur fracture repair using
Table 2 Complications
Control Intervention p value
n = 120 n = 120
Cardiovascular 18 (15%) 13 (11%) 0.336
Respiratory 10 (8%) 12 (10%) 0.655
Cerebrovascular 5 (4%) 0 (0%) 0.024
Acute kidney failure 10 (8%) 11 (9%) 0.819
GI bleed 1 (1%) 2 (2%) 0.561
Confusion 19 (16%) 20 (17%) 0.861
Sepsis 8 (7%) 8 (7%) 1.00
DVT 1 (1%) 0 (0%) 0.316
Wound infection 0 (0%) 2 (2%) 0.156
Delayed healing 0 (0%) 2 (2%) 0.156
UTI 10 (8%) 4 (3%) 0.098
Decubitas 1 (1%) 0 (0%) 0.316
Haematoma 1 (1%) 3 (3%) 0.313
Haematological 13 (11%) 12 (10%) 0.883
Number of patients with one or
more complications (ITT)
61/120 (51%) 55/120 (46%) 0.439
Number of patients with one or
more complications (PP)
61/120 (51%) 43/100 (43%) 0.247
Table 3 Intraoperative fluid volumes and vasopressor doses (mean (sd), min-max, n)
Control Intervention
n = 120 n = 120
Total fluid given 1012.7 (354.0), 200–2000, n = 120 875.0 (456.1), 250–2250, n = 120 0.010
RBC total 344.2 (116.0), 262–549, n = 5 341.8 (129.8), 244–601, n = 7 0.976
Platelets 301.0 (0.0) 301–301, n = 2 n = 0 –
Ephedrine total dose 15.6 (7.9), 6–30, n = 47 15.4 (9.8), 6–36, n = 17 0.912
Metaraminol total dose 3.2 (2.3), 0.2–8.8, n = 48 3.5 (4.5), 0.5–26.5, n = 39 0.597
Phenylephrine total dose 2.3 (1.3), 0.4–5.0, n = 16 2.2 (1.9), 0.1–12.2, n = 76 0.948
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non-invasive technology did not result in a reduction
in post-operative complications or mortality. On the
per-protocol analysis, a reduction in mean length of
stay was seen.
Whilst the lack of effect is at odds with the original
trials using goal-directed fluid therapy in this patient
group (Sinclair et al., 1997; Venn et al., 2002), it mirrors
the effects seen in the more recent trials where a
clinically significant risk reduction was seen that failed
to reach significance (Bartha et al., 2013; Moppett et
al., 2015).
This trial differs from the more recent ones
performed by Bartha and Moppett in various ways;
firstly, we used the NHFS to identify those at higher
risk of morbidity and mortality. The assumption was
that any treatment effect seen from haemodynamic
optimisation would be greater in this group. However,
it may also be that due to the multiple comorbidities,
poor cardiac function and poor outcomes in this
group, the outcome is minimally modifiable. Secondly,
we chose to enrol patients undergoing both spinal
and general anaesthesia, whereas in the work by
Moppett and colleagues, only patients undergoing
spinal anaesthesia were included, and over 90% of
surgery was performed under regional anaesthesia in
the work by Bartha. Whilst there is no data that sug-
gests that one form of anaesthesia is related to better
outcomes in this patient group (White et al., 2016), it
is a potential confounder when comparing the studies.
This was stratified for, however, in the randomisation
procedure. The inclusion of a population that had a
mixture of general and neuraxial anaesthesia is more
reflective of the practice seen in the UK and hence
makes the results more generalisable. Thirdly, we
chose to use a non-invasive measurement of blood
pressure and stroke volume in the form of the Clear-
Sight™ system as opposed to an arterial line based
system that was used in the 2 recent trials. This
approach was chosen as invasive monitoring is rarely
used in this patient group and would represent a
significant change from practice. The ClearSight™
technology provides the same information from a fin-
ger cuff and hence may have greater uptake by the
Table 4 Blood pressure data (AUC)
Blood pressure threshold Group Mean (sd) p value
MAP below 70mmHg Control 0.37 (0.38) 0.044
Intervention 0.28 (0.30)
MAP below 65mmHg Control 0.27 (0.31) 0.029
Intervention 0.18 (0.26)
MAP below 60mmHg Control 0.19 (0.25) 0.043
Intervention 0.12 (0.20)
MAP below 55mmHg Control 0.11 (0.19) 0.100
Intervention 0.07 (0.15)
MAP below 50mmHg Control 0.07 (0.13) 0.063
Intervention 0.03 (0.10)
MAP below 10 % baseline Control 0.68 (0.44) 0.652
Intervention 0.65 (0.38)
MAP below 20 % baseline Control 0.53 (0.43) 0.251
Intervention 0.47 (0.35)
MAP below 30 % baseline Control 0.35 (0.36) 0.067
Intervention 0.27 (0.29)
MAP below 40 % baseline Control 0.19 (0.27) 0.036
Intervention 0.12 (0.19)
MAP below 50 % baseline Control 0.08 (0.18) 0.031
Intervention 0.03 (0.08)
MAP below 60 % baseline Control 0.02 (0.07) 0.009
Intervention 0.00 (0.01)
Fig. 2 Forest plot of included RCTs of cardiac output-guided fluid therapy during hip fracture surgery assessing mortality (30 days, or in-hospital
within 30 days)
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profession as opposed to the increased usage of inva-
sive monitoring. Whilst both systems utilise arterial
waveform analysis, the ClearSight™ system recon-
structs this from a finger artery waveform and uses
pulse contour analysis rather than pulse power ana-
lysis as seen in the LiDCO systems. The technology
failure rate of 15% in this study is of significance and
must be bore in mind by future researchers, with the
majority of failure due to poor signal acquisition due
to cold peripheries and osteoarthritic fingers. On the
per-protocol analysis, a reduction in LOS was seen,
confirmed by the meta-analysis, and hence if a suit-
able technology could be made to work effectively in
this group, then there may be a benefit. Finally, and
similarly to the work by Bartha, we chose to include
a step in the intervention arm that aimed to control
for blood pressure. Hypotension has been shown to
be associated with acute kidney injury and myocardial
injury after non-cardiac surgery (MINS), and a value
below 65 mmHg has been suggested as putting indi-
viduals at a higher risk of these events (Salmasi et al.,
2017; Sun et al., 2015). In addition, hypotension has
been associated with harm in this specific patient
group (White et al., 2016). We chose to use a treat-
ment value of below 30% from baseline, which has a
similar relative risk of injury (Salmasi et al., 2017).
Whilst the incidence and duration of hypotension was
less in the intervention group, there was no statistical
significance in the AUC for MAP below 30% of base-
line [0.35 (0.36) vs. 0.27 (0.29), p = 0.067] representing
a protocol compliance failure for the intervention
group overall. Despite this, there was no association
between any degree or magnitude of hypotension and
outcome in this trial, and the incidence of complica-
tions, including kidney injury or cardiovascular com-
plications, was not different between the groups.
However, MINS was not specifically screened for and
this study was not designed to detect an outcome dif-
ference due to variations in MAP. The currently ac-
cepted value of 65 mmHg is also based on population
data that does not include the group studied in this
trial who have a significant incidence of hypertension
and in perhaps whom a higher cutoff value relating
to outcomes may be seen in this population.
The complication rates in this trial were similar to
those seen in the more recent trials. Bartha, who also
treated hypotension as part of the protocol, reported
a RR of 0.79 (95% CI 0.54–1.16), similar to the OR of
0.73 (95% CI 0.43–1.24) in this trial, whilst Moppett
who did not control for baseline blood pressure
showed RR of 0.91 (95% CI 0.64–1.28) for patients
developing one or more complications. Whilst our
groups were well matched in terms of comorbidities,
there was a significant difference in stroke volume,
with the intervention group having a lower SV at the
start of surgery. This may reflect poorer underlying
cardiovascular function, and hence this group may
have been more compromised compared to the con-
trol group leading to a reduced treatment effect. Fluid
volumes given were also different between the trials
with the intervention group receiving 875 ml of crys-
talloid compared to 1500 ml in the work by Moppett
and colleagues and 1078 ml in the Bartha trial. A
concern is that this may relate to an increased use of
vasopressor. The use of vasopressors is not without
risk, and pure alpha agonists such as phenylephrine
are associated with a reduction in cardiac output and
cerebral blood flow (Cannesson et al., 2012; Ogoh et
al., 2011), depending on preload responsiveness,
which may translate into worse outcomes. However,
we showed no difference in the amount given be-
tween the groups.
A reduction in mean and not median length of stay
was detected in patients treated on a per-protocol
basis. Whilst this analysis was defined a priori, cau-
tion must be used in the interpretation of this result
as the trial was not powered to detect this and the
effect size is borderline. The mean length of stay is
more reflective of the economic impact that an inter-
vention may have on a population, and indeed if this
effect can be repeated then due to the magnitude of
reduction seen, this would have a significant impact
for the NHS. In addition, there was a noticeable re-
duction in the upper quartile limit for the median
Fig. 3 Forest plot of included RCTs of cardiac output-guided fluid therapy during hip fracture surgery assessing post-operative complications
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stay in the intervention group from 32 to 22 days in
keeping with a mean reduction. It may well be that
these metrics represent a reduction in the variation of
care, which in itself has been suggested to lead to im-
proved outcomes.
An updated meta-analysis showed a significant
effect on morbidity with a risk ratio of 0.81 (0.67–
0.98) whilst the effects on mortality remained non-
significant and unchanged. It is interesting to note
that none of the 4 studies included have suggested
harm from the intervention; however, given the po-
tential impact that even a small reduction in either
LOS or complications would have on such a large
population, and the signal seen in meta-analysis, then
a large pragmatically designed multicentre trial that
addresses both fluid management and blood pressure
control is now warranted.
The study has limitations: primarily in that it is under-
powered. We expected a complication rate of 60% in the
control group and this was only 51%. This may reflect
temporal improvements in perioperative care based on
guidelines from groups such as the National Institute for
Healthcare and Excellence, the National Hip Fracture
Database and the Association of Anaesthetists of Great
Britain and Ireland amongst others, and additionally, the
trial was conducted over the best part of 2 years and
there is a chance of a significant Hawthorne effect.
Despite this, it remains the largest randomised
controlled trial of haemodynamic optimisation of hip
fracture patients and adds to the literature and updated
meta-analysis. We chose to use the same basket of com-
plications as those used in the Bartha trial in order that
direct comparison may be made; however, it may be that
these complications are too generic and more procedure
specific and patient-relevant end points are needed. Fi-
nally, protocol compliance may have been suboptimal as
there was no significant difference in patients with a
MAP of less than 30% of baseline and a relatively small
increase in SV. This may reflect the relatively short na-
ture of the surgery and hence a limited opportunity of
optimising patients.
The strengths of the study include a homogenous
population, the inclusion of MAP control in the algo-
rithm, the exclusion of lower risk patients and the fact
that the intervention was performed in the context of
best practice for fractured neck of femur care.
The updated meta-analysis suggests a possible reduc-
tion in complications, and the relative reduction in com-
plications appears consistent throughout the three more
recent trials. Given the significant and growing volume
of surgery undertaken, and the economic impact on
health care, larger studies should address a treatment
strategy where both fluid and blood pressure manage-
ment are addressed.
Appendix 1
Table 5 Definitions of post-operative complications
Complication Definition
Cardiovascular Acute atrial fibrillation and/or troponin-I (> 50 ng∙l−1) and/or angina and/or ECG-detected
ischaemia and/or heart failure (X-ray or clinical symptoms requiring changes in the
post-operative therapy) and/or CT verified pulmonary embolisation
Respiratory Need of oxygen > 4 L/min (to maintain SpO2> 92%) and CRP > 100 and/or pneumonia
diagnosed by X-ray and treated by antibiotics
Cerebrovascular Focal symptoms and CT scan-verified acute pathology of a stroke or a history and
examination consistent with a transient ischaemic attack
Acute kidney failure 30% increase of baseline creatinine or/and < 0.5 ml/h diuresis
Gastrointestinal bleeding Verified by loss of haemoglobin (Hb < 100 g/l) and blood in the faeces
Confusion AMTS or answering the question “Do you think the patient had been more confused lately?”
Sepsis Body temperature < 36° or > 38° and heart rate > 90/min and respiratory rate > 20/min
or pCO2< 4.3 kPa and leukocytes < 4000 cells/mm
3 or > 12 000 cells/mm3
Deep-vein thrombosis When suspected and detected by Doppler ultrasonography
Wound infection Deep and/or superficial with purulent exudate and treated by antibiotics
Delayed healing Superficial or deep wound breakdown needing surgical intervention
Urinary tract infection Positive urine culture and/or new clinical symptoms and CRP > 100
Decubitus Broken skin, but intact subcutaneous tissue or sore involving deep soft subcutaneous
tissue without muscle or tissue loss, including soft tissues
Wound haematoma Needing surgical drainage
Haematological Requirement in the last 24 h of blood products
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Appendix 2
Table 6 POMS scores on post-operative days 3, 5 and 10
Group p value
Control Intervention
Count Column, N (%) Count Column, N (%)
POMS, day 3 score 0 42 35.0 41 34.2 0.617
1 46 38.3 52 43.3
2 19 15.8 20 16.7
3 11 9.2 5 4.2
4 2 1.7 2 1.7
Total 120 100.0 120 100.0
POMS, day 3 0 42 35.0 41 34.2 0.892
>0 78 65.0 79 65.8
Total 120 100.0 120 100.0
POMS, day 5 score 0 56 48.7 57 52.8 0.222
1 37 32.2 40 37.0
2 13 11.3 7 6.5
3 9 7.8 3 2.8
5 0 0.0 1 0.9
Total 115 100.0 108 100.0
POMS, day 5 0 56 48.7 57 52.8 0.542
>0 59 51.3 51 47.2
Total 115 100.0 108 100.0
POMS, day 10 score 0 55 60.4 52 57.1 0.634
1 25 27.5 30 33.0
2 8 8.8 5 5.5
3 2 2.2 3 3.3
4 1 1.1 0 0.0
5 0 0.0 1 1.1
Total 91 100.0 91 100.0
POMS, day 10 0 55 60.4 52 57.1 0.651
>0 36 39.6 39 42.9
Total 91 100.0 91 100.0
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